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Abstract The purpose of the study was to evaluate the
safety and efficacy with the use of BMP-2 for treating
persistent non-unions in children with underlying complex
conditions. Between October 2006 and November 2010 in
our unit, 15 patients were treated with rhBMP-2 to enhance
bone union. There were nine females and six males with a
mean age of 9.5 years (range 4–15) at time of surgery.
Seventy-five per cent of the patients required revision of
internal fixation with insertion of rhBMP-2 to the non-
union site, and the reminder had freshening of the non-
union site with rhBMP-2 application. Patients had under-
gone a mean of 2 (1–5) operations prior to implantation of
rhBMP-2. All the patients in the study group were available
for review with mean follow-up of 44 months (range
21–70). The mean time to union was 16 weeks (range
10–28 weeks). No adverse events related to BMP-2
application were noted in our study group. Healing
occurred clinically and radiographically in 16 of the 17
sites. Our study demonstrates that BMP-2 enhances healing
of the persistent non-unions without any adverse events
Keywords Bone  Congenital abnormalities non-union 
rhBMP-2
Introduction
Autologous bone grafting (ABG) has osteogenic, osteoin-
ductive and osteoconductive properties and is the gold-
standard biological treatment for non-union [1, 2]. How-
ever, limited availability and donor site morbidity limit its
use [3, 4]. In 1965, Marshal R Urist discovered a substance
within the extracellular matrix of bone that induced new
bone formation when implanted into extraskeletal sites in a
host. This substance triggers a proliferation of undifferen-
tiated mesenchymal cells and the formation of osteopro-
genitor cells to form bone. It was called bone morphogenic
protein (BMP). By 1988, molecular clones had been
characterised and the amino acid sequence from a highly
purified bovine bone preparation was derived. This led to
the isolation of human complimentary DNAs, recognised
subsequently as a member of the superfamily of trans-
forming growth factor b. At least 20 human variants of
BMPs that possess varying degrees of osteoinductive
activity have been identified since [5].
Two (BMP-2 and BMP-7) have been the subject of
intense research for treatment of non-union and are avail-
able currently as recombinant protein molecules of human
genes [5]. The Food and Drug Administration (FDA) and
the European agency for the evaluation of medical products
have approved the use of BMP-2 as bone graft substitute in
adults with open tibial fractures and those undergoing
anterior lumbar inter-body spinal fusion as an adjunct to
standard care by internal fixation [6–10].
In addition to the approved use, there have been reports
of use in an off-label fashion in children undergoing sur-
gery for spinal and orthopaedic conditions [11–13, 18, 19].
However, there are limited published data on the use and
outcomes of BMP-2 in revision non-union surgery in the
paediatric population.
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In children, fractures and corrective osteotomies heal
well mostly. However, union may be difficult to achieve in
patients with skeletal dysplasias, congenital deficiencies of
the limbs and some complex fractures. This is our expe-
rience with the use of BMP-2 in children undergoing
revision surgery for persistent non-union.
Materials and methods
We undertook a retrospective review of all the patients who
received rhBMP as a part of their treatment at the Sheffield
Children’s Hospital between October 2006 and November
2010. This review was approved by the research and
development department of our institution. In all patients,
the decision to use rhBMP-2 was made at a multidisci-
plinary team meeting. We had approval from the hospital
pharmacy department and also obtained informed consent
from the parents of our patients for the use of rhBMP-2.
Clinical data for each patient were gathered from the
medical records and included demographics, anatomical
site, diagnosis, initial treatment, number and type of pre-
vious operations, operative details at the time of rhBMP-2
use, time to union and the length of follow-up (see
Table 1).
Nineteen patients (21 surgical procedures) received
rhBMP-2 as a part of their treatment during the study
period. Four patients were excluded as they were either
older than 18 years, had autologous bone graft in addition
to rhBMP-2 or had a spinal fusion procedure. The final
sample was comprised of 15 patients (17 surgical proce-
dures). Case 4 required two episodes of rhBMP-2 appli-
cation to a femoral non-union site and case 10 had bilateral
application of rhBMP-2 to tibial non-union sites at differ-
ent stages. The mean age of these patients at the time of
rhBMP-2 use was 9.5 years (range 4–15 years). Nine were
female and six male (Table 1).
All the patients had a persistent non-union or pseu-
doarthrosis despite previous surgery to achieve union. With
the exception of one case (case 8) that was an atrophic non-
union, the remainder had radiographic features of olig-
otrophic non-union (Table 1).
The patients had undergone a mean of 2 (range 1–5)
previous surgical procedures prior to the use of rhBMP-2.
The surgical procedures included resection of pseu-
doarthrosis and autologous bone grafting in 10 patients
(62 %), intramedullary fixation with rods, fixation with a
plate and screws or application of external fixator.
The predominant primary diagnosis was osteogenesis
imperfecta (5 patients). The other diagnoses were proximal
femoral focal deficiency (2 patients), neurofibromatosis
with pseudoarthrosis of the tibia (2 patients), non-union
after comminuted fractures (2 patients), achondroplasia,
arthrogryposis, Coats’ plus disease and a femoral fracture
in a patient with both Down’s syndrome and Perthes
disease.
The senior authors (JAF and SJ) evaluated patients for
clinical evidence of healing by pain and tenderness at the
non-union site and the ability to weight bear on the affected
limb with the orthosis. The radiographs were evaluated
independently for any complications and signs of healing.
Friedlander’s criterion (the presence of bone bridging at the
site of non-union in at least one view) was used [20]. The
non-union was considered healed if it fulfilled radiological
and clinical criteria.
Operative technique
All the surgical procedures were performed under general
anaesthetic. Prophylactic antibiotic was administered at the
time of induction and two further doses given at 8 and 16 h
postsurgery. Using a tourniquet, the non-union site was
exposed through a longitudinal skin incision. Fibrous tissue
and avascular bone were excised until healthy bone ends
were exposed. In some cases of tibial non-union, it was
necessary to undertake a fibular osteotomy, done through a
separate lateral skin incision.
The next stage of the surgery involved a revision of the
fixation device if required. For intramedullary nails, the
medullary canal of the proximal and distal segments was
drilled with increasingly larger drill bits to accommodate
the larger nails. In those patients with external fixators
in situ, these were adjusted accordingly and some com-
pression applied.
BMP-2 was reconstituted with sterile water to a con-
centration of 1.5 mg/ml and a bovine collagen sponge used
as delivery matrix. After at least 15 min of soak time and
just before closure of the surgical wound, the BMP-2-im-
pregnated sponge was cut into rectangular pieces and
implanted directly over the bone ends. Demineralised bone
matrix (DBX) was placed over the BMP-2 in patients with
large defects. The amount of BMP-2 used was determined
by the size of the bone cavity or defect. Autologous bone
graft was not used in any of the cases.
All the patients were allowed to commence partial
weight bearing once the surgical wound had healed. Clin-
ical and radiological follow-up was undertaken at regular
intervals until union was achieved.
Results
None of the patients was observed to have a septic non-
union. At the time of revision surgery with rhBMP-2, 75 %
of the patients required revision of the previous fixation
device. Twelve patients required revision fixation at the
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time of BMP-2 insertion that included Sheffield telescopic
rods for the tibia and femur in five and two patients,
respectively, whereas Fassier–Duval telescopic rods were
used in the tibia of two patients. In two patients with
femoral non-unions, plates were used, and in one patient,
an Ilizarov ring fixator was used to stabilise the femur.
All the patients in the study group were available for
review at a mean follow-up of 44 months (range 21–70).
The mean time to union was 16 weeks (range
10–28 weeks) (Fig. 1a, c). Clinical and radiological heal-
ing was observed in 16 of the 17 sites at the last follow-up.
One patient (case 8) with Coats’ plus disease was treated
with BMP-2 and an Ilizarov fixator for tibial non-union
10 months after the index surgery and failed to heal. Fur-
ther autologous bone grafting was performed, and at
6 months postoperatively the bone has failed to unite and
the patient is awaiting further surgery.
No local or systemic complications attributable to BMP-
2 were noted in any of our patients. In particular, none of
our patients had a wound breakdown, local soft tissue
calcification or heterotrophic ossification.
Discussions
Bone morphogenic proteins possess good osteoinductive
properties that enhance healing and are used in the treat-
ment of adult patients with recalcitrant non-unions and
spinal fusion procedures successfully to facilitate
union/fusion [7, 8, 20]. The manufacturers of commercially
available recombinant human BMP-2 have stated that it is
contraindicated for use in the paediatric population because
they have not been able to provide data that establish the
safety and efficiency of BMP-2 in children below 18 years
of age. There have been reports of use of BMPs in the
paediatric population [11–19] with most as case reports
[13, 14] and small case series [15, 17–19]; the prevalent
clinical condition for its use was congenital pseudoarthro-
sis of the tibia [12, 15–19].
In comparison, use of rhBMP-7(OP-1) for treating non-
union and congenital pseudoarthrosis of the tibia in the
paediatric population [14–17] had mixed success. Lee et al.
reported on five patients with congenital pseudoarthrosis of
the tibia treated using bone graft, rhBMP-7 and fixation.
Union was achieved in only one of the five cases, and it
was felt that variables in the surgical technique contributed
to the poor outcome [15]. Other authors have reported
reasonable outcomes [14, 16–18]. The results of these
studies suggest that rhBMP-7 should be combined with
autologous bone graft and optimum fixation of the pseu-
doarthrosis is required.
The current literature describes rhBMP-2 used mostly
for the treatment of congenital pseudoarthrosis of tibia in
Fig. 1 This 12-year-old patient with congenital pseudoarthrosis of
the tibia had multiple surgical procedures to enhance the healing of
non-union. a Preoperative radiograph showing the non-union of the
pseudoarthrosis with growing rod in situ. b Intraoperative images
illustrating the revision intramedullary nailing and BMP-2 insertion.
c Anteroposterior view radiograph at 14 weeks after initial surgery
showing healing at the pseudoarthrosis site
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the paediatric population [18, 19]. Spiro et al. [18] reported
four children with congenital pseudarthrosis of the tibia
treated with intramedullary stabilisation, Ilizarov external
fixators and rhBMP-2. Only one out of four had previous
failed surgery. Radiological union was achieved at a mean
of 3.5 months postoperatively with a mean follow-up of
31 months. They concluded that the initial rate of union
may be improved and the time to union reduced with this
strategy. Richards et al. [19] reported on seven children
with CPT treated using rhBMP-2, autologous bone graft
and intramedullary rodding. Two patients had failed pre-
vious surgery. Radiological union was achieved in five
patients at a mean of 6.4 months. The average follow-up
was 72 months, and no adverse effect of BMP was
observed. They also noted an improvement in the time to
initial union. Their average of 6.4 months compared
favourably with 16 months reported by Dobbs et al. [22]
who treated a similar group of patients using autologous
bone graft and intramedullary rodding but without BMP.
In this series, we observed a mean time to union of
16 weeks. This compares favourably with the reports of
Spiro et al. (14 weeks) and Richards et al. (26 weeks). This
may be because most of our cases were not congenital
pseudoarthroses of the tibia. The time to union of the two
cases of CPT in this study was 12 and 14 weeks, respec-
tively. The non-unions in this series were due to multiple
factors, viz. biology and stability. RhBMP-2 is not effec-
tive in the presence of instability at the non-union site. The
one patient in this study who failed union despite using
rhBMP-2 and an Ilizarov fixator was a case of Coats’ plus
disease with a tibial non-union (case 8). Further autologous
bone grafting failed, and further surgery is being planned.
We believe the failure to achieve healing is related to the
underlying diagnosis and not surgical technique. It is
established that congenital defects decrease fusion rates
[1].
This report contains the second largest number of
patients (15 patients) but with a longer follow-up than that
published by Oetgen et al. Fifty-three of 81 patients in their
series were skeletally immature, and BMP-2 was used
mostly as part of spinal surgery. The report was focussed
on the complications associated with the use of BMP-2
[12], citing an overall complication of 17.5 % in 81
patients. The complications included excessive wound
discharge and swelling, wound dehiscence, deep infection,
enlargement of optic glioma, compartment syndrome,
progressive myelopathy and dural fibrosis. They believed
that only one of the complications may have been directly
related to the use of BMP-2; this was dural fibrosis asso-
ciated with motor weakness after exposure of the spinal
cord to rhBMP-2 [12].
Ritting et al. [13] reported a case of massive inflam-
matory reaction following the use of rhBMP-2 to treat an
ulnar non-union in a child. Circulating antibodies against
type 1 collagen and anti-BMP-2 antibodies have been
detected in a smaller number of patients treated with BMP,
but these studies have concluded that there is insufficient
evidence to establish a relationship between these anti-
bodies and the absence of ossification [6, 20, 21].
Although there is a theoretical risk of adverse events in
association with the use of BMP in skeletally immature
patients, this is not confirmed in the literature. In the fol-
low-up period of this study, we did not observe any local or
systemic adverse events related directly to the use of BMP-
2. The patients and the families in this study were warned
of the risk of developing adverse effects and complications
such as deep infection, a severe inflammatory reaction,
neuralgia, resorption of bone, compartment syndrome,
heterotrophic ossification and local nerve compression.
There are limitations to this study. This is a retrospective
review of a small sample described by the common feature
of having had failed attempts to treat a non-union. The
sample was heterogeneous and without a control group for
comparison. Alteration to the biomechanics (adjustment of
fixation method) across the non-union would have influ-
enced the results as would have use of the rhBMP.
In conclusion, this review describes successful use of
rhBMP-2 as a part of a treatment strategy for persistent
non-unions in children who have failed to achieve bone
healing despite standard methods of treatment.
Conflict of interest The authors declare that they have no conflict
of interest.
Ethical approval This was a retrospective study and for this type of
study formal consent is not required.
Informed consent Informed consent was obtained from all the
individual participants included in the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Megas P (2005) Classification of non-union. Injury 36(Supp
4):S30–S37
2. Phieffer LS, Goulet JA (2006) Delayed unions of the tibia. JBJS
[Am] 88(1):206–216
3. Goulet JA, Senunas LE, DeSilva GL, Greenfield ML (1997)
Autogenous iliac crest bone graft. Complications and functional
assessment. CORR 339:76–81
4. Schnee CL, Freese A, Weil RJ (1997) Analysis of harvest mor-
bidity and radiographic outcome using autograft for anterior
cervical fusion. Spine 22:222–227
Strat Traum Limb Recon (2016) 11:53–58 57
123
5. De Biase P, Capanna R (2005) Clinical applications of BMPs.
Injury 36(Suppl 3):S43–S46
6. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y,
Arbel R (2002) BMP-2 Evaluation in Surgery for Tibial Trauma
(BESTT) Study Group. Recombinant human bone morphogenetic
protein-2 for treatment of open tibial fractures: a prospective,
controlled, randomized study of four hundred and fifty patients.
J Bone Joint Surg Am 84:2123–2134
7. Boden SD, Kang J, Sandhu H, Heller JG (2002) Use of recom-
binant human bone morphogenetic protein-2 to achieve postero-
lateral lumbar spine fusion in humans: a prospective, randomized
clinical pilot trial: 2002 Volvo Award in clinical studies. Spine
27:2662–2673
8. Burkus JK, Transfeldt EE, Kitchel SH, Watkins RG, Balderston
RA (2002) Clinical and radiographic outcomes of anterior lumbar
interbody fusion using recombinant human bone morphogenetic
protein-2. Spine 27:2396–2408
9. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb
LX (2006) Recombinant humanBMP-2 and allograft compared
with autogenous bone graft for reconstruction of diaphyseal tibial
fractures with cortical defects. A randomized, controlled trial.
J Bone Joint Surg Am 88:1431–1441
10. Krause F, Younger A, Weber M (2008) Recombinant human
BMP-2 and allograft compared with autogenous bone graft for
reconstruction of diaphyseal tibial fractures with cortical defects.
J Bone Joint Surg Am 90:1168
11. Abd-El-Barr MM, Cox JB, Antonucci MU, Bennett J, Murad GJ,
Pincus DW (2011) Recombinant human bone morphogenetic
protein-2 as an adjunct for spine fusion in a pediatric population.
Pediatr Neurosurg 47(4):266–271
12. Oetgen ME, Richards BS (2010) Complications associated with
the use of bone morphogenetic protein in pediatric patients.
J Pediatr Orthop 30:192–198
13. Ritting AW, Weber EW, Lee MC (2012) Exaggerated inflam-
matory response and bony resorption from BMP-2 use in a
pediatric forearm non-union. J Hand Surg Am 37(2):316–321
14. Dohin B, Dahan-Oliel N, Fassier F, Hamdy R (2009) Enhance-
ment of difficult nonunion in children with osteogenic protein-1
(OP-1): early experience. Clin Orthop Relat Res
467(12):3230–3238
15. Lee FY, Sinicropi SM, Lee FS, Vitale MG, Roye DP Jr, Choi IH
(2006) Treatment of congenital pseudarthrosis of the tibia with
recombinant human bone morphogenetic protein-7 (rhBMP-7). A
report of five cases. J Bone Joint Surg Am 88(3):627–633
16. Birke O, Schindeler A, Ramachandran M, Cowell CT, Munns CF,
Bellemore M (2010) Preliminary experience with the combined
use of recombinant bone morphogenetic protein and bisphos-
phonates in the treatment of congenital pseudarthrosis of the tibia.
J Child Orthop 4(6):507–517
17. Fabeck L, Ghafil D, Gerroudj M, Baillon R, Delince´ P (2006)
Bone morphogenetic protein-7 in the treatment of congenital
pseudarthrosis of the tibia. J BoneJoint Surg Br 88:116–118
18. Spiro AS, Babin K, Lipovac S, Stenger P, Mladenov K, Rup-
precht M (2011) Combined treatment of congenital pseu-
darthrosis of the tibia, including recombinant human bone
morphogenetic protein-2: a case series. J Bone Joint Surg Br
93(5):695–699
19. Richards BS, Oetgen ME, Johnston CE (2010) The use of
rhBMP-2 for the treatment of congenital pseudarthrosis of the
tibia: a case series. J Bone Joint Surg [Am] 92-A:177–185
20. Friedlaender GE, Perry CR, Cole JD, Cook SD, Cierny G,
Muschler GF (2001) Osteogenic protein-1 (Bone morphogenetic
protein-7) in the treatment of tibial nonunions. J Bone Joint Surg
Am 83-A(suppl 1):S151–S158
21. Geesink RG, Hoefnagels NH, Bulstra SK (1999) Osteogenic
activity of OP-1 bone morphogenetic protein (BMP-7) in a
human fibular defect. J Bone Joint Surg Br 81(4):710–718
22. Dobbs MB, Rich MM, Gordon JE, Szymanski DA, Schoenecker
PL (2005) Use of an intramedullary rod for the treatment of
congenital pseudarthrosis of the tibia. Surg Tech Suppl 1(Pt
1):33–40
58 Strat Traum Limb Recon (2016) 11:53–58
123
